Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCCB2R selective benzimidazoles reveal unexpected intrinsic properties

被引:19
作者
Nimczick, Martin [1 ,2 ]
Pemp, Daniela [3 ]
Darras, Fouad H. [2 ]
Chen, Xinyu [1 ,2 ]
Heilmann, Joerg [3 ]
Decker, Michael [1 ,3 ]
机构
[1] Univ Wurzburg, Inst Pharm & Lebensmittelchem, D-97074 Wurzburg, Germany
[2] Univ Regensburg, Inst Pharm, Lehrstuhl Pharmazeut Chem 1, D-93053 Regensburg, Germany
[3] Univ Regensburg, Inst Pharm, Lehrstuhl Pharrnazeut Biol, D-93053 Regensburg, Germany
关键词
Bivalent ligand; Cannabinoid receptor; CB2; Benzimidazole; ENDOCANNABINOID SYSTEM; ACTIVE CONSTITUENT; AGONISTS; 5-SULFONYL-BENZIMIDAZOLES; PHARMACOLOGY; DERIVATIVES; ANTAGONIST; AFFINITY; KAPPA; MU;
D O I
10.1016/j.bmc.2014.06.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The design of bivalent ligands targeting G protein-coupled receptors (GPCRs) often leads to the development of new, highly selective and potent compounds. To date, no bivalent ligands for the human cannabinoid receptor type 2 (hCB(2)R) of the endocannabinoid system (ECS) are described. Therefore, two sets of homobivalent ligands containing as parent structure the hCB(2)R selective agonist 13a and coupled at different attachment positions were synthesized. Changes of the parent structure at these positions have a crucial effect on the potency and efficacy of the ligands. However, we discovered that bivalency has an influence on the effect at both cannabinoid receptors. Moreover, we found out that the spacer length and the attachment position altered the efficacy of the bivalent ligands at the receptors by turning agonists into antagonists and inverse agonists. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3938 / 3946
页数:9
相关论文
共 40 条
[1]  
Abadi AH, 2002, ARCH PHARM, V335, P367, DOI 10.1002/1521-4184(200211)335:8<367::AID-ARDP367>3.0.CO
[2]  
2-C
[3]   Cannabinoid receptors: nomenclature and pharmacological principles [J].
Console-Bram, Linda ;
Marcu, Jahan ;
Abood, Mary E. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 38 (01) :4-15
[4]   The endocannabinoid system: Physiology and pharmacology [J].
de Fonseca, FR ;
Del Arco, I ;
Bermudez-Silva, FJ ;
Bilbao, A ;
Cippitelli, A ;
Navarro, M .
ALCOHOL AND ALCOHOLISM, 2005, 40 (01) :2-14
[5]   An introduction to the endocannabinoid system: from the early to the latest concepts [J].
De Petrocellis, Luciano ;
Di Marzo, Vincenzo .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (01) :1-15
[6]   Agonistic and antagonistic bivalent ligands for serotonin and dopamine receptors including their transporters [J].
Decker, Michael ;
Lehmann, Jochen .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (04) :347-353
[7]   Synthesis and Opioid Receptor Binding Affinities of 2-Substituted and 3-Aminomorphinans: Ligands for μ, κ, and δ Opioid Receptors [J].
Decker, Michael ;
Si, Yu-Gui ;
Knapp, Brian I. ;
Bidlack, Jean M. ;
Neumeyer, John L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (01) :402-418
[8]   Univalent and Bivalent Ligands of Butorphan: Characteristics of the Linking Chain Determine the Affinity and Potency of Such Opioid Ligands [J].
Decker, Michael ;
Fulton, Brian S. ;
Zhang, Bin ;
Knapp, Brian I. ;
Bidlack, Jean M. ;
Neumeyer, John L. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) :7389-7396
[9]   DIMERIC CANNABINOIDS WITH AN ETHANE BRIDGE [J].
EIDEN, F ;
GERSTLAUER, C .
ARCHIV DER PHARMAZIE, 1981, 314 (12) :995-1006
[10]   Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties [J].
Fernandez-Fernandez, Cristina ;
Decara, Juan ;
Bermudez-Silva, Francisco J. ;
Sanchez, Eva ;
Morales, Paula ;
Gomez-Canas, Maria ;
Gomez-Ruiz, Maria ;
Callado, Luis F. ;
Goya, Pilar ;
Rodriguez de Fonseca, Fernando ;
Isabel Martin, M. ;
Fernandez-Ruiz, Javier ;
Javier Meana, J. ;
Jagerovic, Nadine .
ARCHIV DER PHARMAZIE, 2013, 346 (03) :171-179